Market Overview

Sequenom Says Genetic Test Predicts Progression Risk

Related SQNM
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4
Mid-Day Market Update: U.S. Stocks Edge Higher; G-III Apparel Shares Jump On Upbeat Results

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), presented results from a study of its RetnaGene AMD laboratory-developed test to predict risk of disease progression during the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago.

Posted-In: News FDA


Related Articles (SQNM)

Around the Web, We're Loving...

Get Benzinga's Newsletters